Prognia
Drug Database
🇪🇺EU · EMAAuthorisedATC: J07AE01

Dukoral(recombinant cholera toxin B subunit;vibrio cholerae 01)

Cholera;Immunization

Marketing Authorisation Holder: Valneva Sweden AB

EMA Authorisation: 28/04/2004

INN: cholera vaccine (inactivated, oral)

Indication

Dukoral is indicated for active immunisation against disease caused by Vibrio cholerae serogroup O1 in adults and children from 2 years of age who will be visiting endemic/epidemic areas. The use of Dukoral should be determined on the basis of official recommendations taking into consideration the variability of epidemiology and the risk of contracting disease in different geographical areas and travelling conditions. Dukoral should not replace standard protective measures. In the event of diarrhoea measures of rehydration should be instituted.

Official EMA Resources

View on EMA (ema.europa.eu)

AI Drug & Interaction Analysis

Free account required

Ask Prognia AI about Dukoral — dosing recommendations, drug interactions, and current guideline evidence from ESC, EMA, NICE and more.

Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.